Truncated IGF-1 variant missing the first 3 amino acids, resulting in reduced IGFBP binding and enhanced local anabolic potency.
Last Updated: May 2026
IGF-1 DES (IGF-1 DES(1-3)) is a truncated IGF-1 variant lacking the first three N-terminal amino acids (Gly-Pro-Glu), resulting in substantially reduced binding to IGF-binding proteins (IGFBPs) and enhanced local anabolic potency. It has a very short circulating half-life and primary action at the injection site, distinguishing it from the long-acting IGF-1 LR3. IGF-1 DES is not approved for any medical indication and is sold as a research-use-only compound by third-party laboratories.
IGF-1 DES is native human IGF-1 with the first three N-terminal amino acids (Gly-Pro-Glu) removed, leaving a 67-amino-acid peptide that has substantially reduced affinity for IGF-binding proteins (IGFBPs) but retains full IGF-1 receptor activation. Because IGFBPs normally bind ~99% of circulating IGF-1 and modulate its bioavailability, removing IGFBP affinity makes the DES variant more readily available at receptor sites — but only locally and briefly, as systemic clearance is rapid. Half-life is short (minutes to a few hours). Evidence level: Preclinical extensive (cell culture, rodent muscle models); no published human clinical trials.
Preclinical studies have demonstrated potent local anabolic effects on muscle protein synthesis and satellite cell activation, with IGF-1 DES showing 2–10x greater potency than native IGF-1 in some cell culture systems. The effect profile is primarily local — short systemic half-life means injected DES acts at and near the injection site rather than producing whole-body IGF-1 elevation. No published human clinical trial data exists as of May 2026. Evidence level: Preclinical (cell culture and rodent); no human clinical trials.
IGF-1 DES, IGF-1 LR3, and native IGF-1 (mecasermin) all activate IGF-1 receptors but with substantially different pharmacokinetics and use cases. DES is local-acting and short-duration; LR3 is systemic and long-acting; mecasermin is the approved native form.
| IGF-1 variant | Modifications | Half-life | Primary effect | FDA status |
|---|---|---|---|---|
| Native IGF-1 (mecasermin, Increlex) | None (recombinant native sequence) | ~10 min | Systemic, IGFBP-bound | FDA-approved (severe primary IGFD) |
| IGF-1 LR3 | Arg-3 + 13-AA N-terminal extension | ~20–30 hours | Systemic, sustained | Not approved |
| IGF-1 DES | N-terminal Gly-Pro-Glu removed | Minutes–hours | Local, transient | Not approved |
The local-action profile makes systemic side effects less prominent than with IGF-1 LR3 or native IGF-1 at equivalent doses — sustained systemic IGF-1 elevation is minimal because of rapid clearance. Injection-site reactions are the most common reported effect. Hypoglycemia risk is lower than with IGF-1 LR3 due to the shorter systemic exposure. Long-term safety in humans at sustained research-use dosing is unestablished. Evidence level: Preclinical safety; human long-term unestablished.
IGF-1 DES is not approved for any medical indication anywhere in the world as of May 2026. Native IGF-1 (mecasermin, Increlex) is FDA-approved for severe primary IGF-1 deficiency, but the truncated DES variant has no approval. IGF-1 DES is sold strictly as a research-use-only compound by third-party laboratories. Regulatory context in are peptides legal regulatory status by country.
IGF-1 DES is a 67-amino-acid peptide — substantially larger than most GH-axis peptides — making synthesis quality control variable and endotoxin testing critical. The structural distinction (3 amino acids removed from native IGF-1) requires mass spectrometry identity confirmation to verify versus native IGF-1 or other IGF-1 analogs. Independent HPLC purity testing is the standard quality signal. Guidance in how-to-test-peptides hub.
Peptigrity purchases IGF-1 DES vials anonymously at standard customer pricing, sends them to ISO-accredited third-party labs for HPLC, mass spectrometry, and endotoxin analysis, and publishes the unedited certificate of analysis. Methodology in how we calculate trust scores.
IGF-1 DES has short half-life and primarily local effects at the injection site; IGF-1 LR3 has long half-life (20–30 hours) and systemic effects. Researchers use DES for site-specific anabolic effects and LR3 for sustained systemic IGF-1R activation. They are not interchangeable.
IGF-1 DES is legal to purchase as a research chemical for laboratory use in most jurisdictions, but it is not approved for human consumption. Country breakdown in peptide legal status guide.
No active clinical development program for IGF-1 DES exists as of May 2026. FDA approval is unlikely without renewed development by a pharmaceutical sponsor. Native IGF-1 (mecasermin) is FDA-approved for severe primary IGF-1 deficiency.
Less than IGF-1 LR3 because of the much shorter systemic half-life, but still some risk — IGF-1 receptor activation can produce insulin-like effects on glucose handling. Anyone considering use should be aware of the underlying axis biology and consult a licensed physician.
Yes. IGF-1 and analogs are on the WADA Prohibited List (Section S2 — Peptide Hormones). For drug-testing context, see do peptides show up on drug tests.
No. IGF-1 DES is not approved for human consumption and Peptigrity is an independent review platform, not a medical authority. Research-use dosing in community protocols varies. Anyone considering use should consult a licensed physician.
This section is for educational and informational purposes only and does not constitute medical advice. IGF-1 DES is not approved by the FDA or any other regulator for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.
Real protocols and questions from members — independent of vendors, never sponsored.
Sign in to ask a question.
Every submitted test helps the community verify purity across brands. Free, fast, independent.